Search

AbstractThis study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians’ diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease.

Introduction. Growth depends on genetic, metabolic and also hormonal factors. Growth depends on health, the supply of nutrients and a properly functioning nervous system. Growth hormone deficiency is a disorder that does not cause typical somatic symptoms, but has a negative impact on a child’s life and functioning in society. Aim. The aim of the study was to evaluate the satisfaction of parents with the treatment with human recombinant growth hormone in children with somatropin-induced pituitary insufficiency. Material and Methods. The studies were conducted among parents of children with somatropin-induced pituitary insufficiency treated with human recombinant growth hormone in the Provincial Complex Hospital of Rydygier in Toruń at the Department of Paediatrics, Endocrinology, Diabetology and Paediatric Neurology, from 1.12.2019 to 1.02.2020. 69 parents of children treated with recombinant growth hormone were included in the study. The mean age of parents of children participating in the study was 11.77 ± 3.53 years. The research tools were: a record, self-questionnaires and the standardized KIDSCREEN-52 health questionnaire for children and adolescents in the version for parents. Results. The highest mean values of the standardized KIDSCREEN-52 scale in the version for parents were shown for the following areas: moods and emotions (84.55 ± 12.73), relationships with parents and home (81.83 ± 10.88) and social acceptance (89.86 ± 12.86). It was found that the higher the quality of the area of physical well-being and health, the lower the need for mental preparation of the child for hospital visits in connection with treatment — rS = 0.254, p = 0.035. The analyses showed that the higher the quality of the area of social support and colleagues, the smaller the difficulty resulting from the treatment-related visits to the hospital ward — rS = 0.266, p = 0.027, there was also a lower need to mentally prepare the child for hospital visits — rS = 0.261, p = 0.030. Conclusions. Satisfaction with treatment with recombinant growth hormone depends on the duration of treatment and the growth results achieved. Parents of children with hypopituitarism are satisfied with the treatment with recombinant growth hormone and assess the treatment positively. (JNNN 2021;10(3):120–125)

This study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians' diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease. [ABSTRACT FROM AUTHOR]